158 related articles for article (PubMed ID: 11792604)
1. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.
Ravn P; Neugebauer G; Christiansen C
Bone; 2002 Jan; 30(1):320-4. PubMed ID: 11792604
[TBL] [Abstract][Full Text] [Related]
2. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
Ravn P; Clemmesen B; Riis BJ; Christiansen C
Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
[TBL] [Abstract][Full Text] [Related]
3. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
4. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
Ravn P; Christensen JO; Baumann M; Clemmesen B
Bone; 1998 May; 22(5):559-64. PubMed ID: 9600792
[TBL] [Abstract][Full Text] [Related]
5. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C
Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
[TBL] [Abstract][Full Text] [Related]
7. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
[TBL] [Abstract][Full Text] [Related]
8. Oral weekly ibandronate prevents bone loss in postmenopausal women.
Tankó LB; Felsenberg D; Czerwiński E; Burdeska A; Jonkanski I; Hughes C; Christiansen C;
J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
Christgau S; Rosenquist C; Alexandersen P; Bjarnason NH; Ravn P; Fledelius C; Herling C; Qvist P; Christiansen C
Clin Chem; 1998 Nov; 44(11):2290-300. PubMed ID: 9799756
[TBL] [Abstract][Full Text] [Related]
11. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
12. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
[TBL] [Abstract][Full Text] [Related]
13. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
15. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
16. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.
Tankó LB; Mouritzen U; Lehmann HJ; Warming L; Moelgaard A; Christgau S; Qvist P; Baumann M; Wieczorek L; Hoyle N; Christiansen C
Bone; 2003 Jun; 32(6):687-93. PubMed ID: 12810176
[TBL] [Abstract][Full Text] [Related]
17. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
18. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
19. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Clemmesen B; Christiansen C
Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
